Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments: A Multicenter Cohort Study - PubMed
a day ago
- #Disease-Modifying Therapies
- #Multiple Sclerosis
- #PML
- JC virus (JCV) reactivation causing progressive multifocal leukoencephalopathy (PML) is a complication in MS patients treated with disease-modifying therapies (DMTs).
- Natalizumab (NTZ) is most frequently associated with PML, but it also occurs with S1P-RM, DMF, and ocrelizumab.
- The study analyzed 94 MS patients with JCV-associated pathology from 42 centers (2009-2022).
- Higher pre-PML disability, elevated CSF JCV viral load, and symptomatic presentation at onset were predictors of worse outcomes.
- PML-IRIS was associated with better outcomes, while PlEx and corticosteroid use had no negative effect.
- 12-month survival was 91.5%, with a median mRS of 3.